Literature DB >> 10968325

Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy.

M Heep1, M Kist, S Strobel, D Beck, N Lehn.   

Abstract

In a study to determine secondary resistance among Helicobacter pylori isolates, gastroenterologists from several German cities submitted over a 3-year period to centre A (Regensburg) or centre B (Freiburg) gastric biopsies from patients in whom one or more therapies to eradicate Helicobacter pylori had failed. Rates of resistance among the collections of 302 (centre A) and 252 (centre B) isolates were, respectively, as follows: to metronidazole, 75% and 66%; to clarithromycin, 58% and 49%; to amoxicillin, 0%; to ciprofloxacin, 9%; to doxycycline, 0%; and to rifampin, 0%. Resistance to clarithromycin was associated with metronidazole resistance in 89% and 85% of the isolates in centre A and centre B, respectively.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10968325     DOI： 10.1007/s100960000288

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  32 in total

Review 1.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

2.  Eradication of H. pylori Infection: the Challenge is on if Standard Therapy Fails.

Authors:  Ulrich R M Bohr; Peter Malfertheiner
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

3.  Helicobacter pylori and antibiotic resistance.

Authors:  Francis Megraud
Journal:  Gut       Date:  2007-11       Impact factor: 23.059

Review 4.  Third-line rescue therapy for Helicobacter pylori infection.

Authors:  Rossella Cianci; Massimo Montalto; Franco Pandolfi; Giovan-Battista Gasbarrini; Giovanni Cammarota
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

Review 5.  Second and third line treatment options for Helicobacter pylori eradication.

Authors:  Mingjun Song; Tiing Leong Ang
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

6.  Real-time PCR screening for 16S rRNA mutations associated with resistance to tetracycline in Helicobacter pylori.

Authors:  Erik Glocker; Marco Berning; Monique M Gerrits; Johannes G Kusters; Manfred Kist
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

7.  Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial.

Authors:  Josip Bago; Karolina Majstorović; Zeljka Belosić-Halle; Nastja Kućisec; Vinko Bakula; Monika Tomić; Petra Bago; Rosana Troskot
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-04-15       Impact factor: 3.944

Review 8.  Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line.

Authors:  Simona Di Caro; Lucia Fini; Yayha Daoud; Fabio Grizzi; Antonio Gasbarrini; Antonino De Lorenzo; Laura Di Renzo; Sara McCartney; Stuart Bloom
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

9.  In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori.

Authors:  Morris O Makobongo; Tchelet Kovachi; Hanan Gancz; Amram Mor; D Scott Merrell
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

10.  Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods.

Authors:  L M Best; D J M Haldane; M Keelan; D E Taylor; A B R Thomson; V Loo; C A Fallone; P Lyn; F M Smaill; R Hunt; C Gaudreau; J Kennedy; M Alfa; R Pelletier; S J O Veldhuyzen Van Zanten
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.